Gateway Blog

Gateway Blog

New Treatment Approved for Advanced Ovarian Cancer

By Admin at 25 Jan 2017

Women with advanced ovarian cancer may have a new option for treatment. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Rubraca (rucaparib), a poly ADP-ribose polymerase (PARP) inhibitor.

0 comments posted

Immunotherapy Could Raise Survival Rates for Ovarian Cancer

By Admin at 13 Jul 2016

A new study showed that incorporating immunotherapy into ovarian cancer treatment might combat chemotherapy resistance and improve survival rates.

0 comments posted

Blood Test May Successfully Screen for Early-Stage Ovarian Cancer

By Admin at 5 Jan 2016

Unfortunately, only about 20 percent of ovarian cancers are currently detected in the early stages. A new blood test may change that, however, according to a study by researchers at the Georgia Institute of Technology.

0 comments posted

Overcoming Chemotherapy Resistance in Ovarian Cancer

By Admin at 9 Dec 2015

One of the main hurdles to increasing outcomes among ovarian cancer patients is resistance to chemotherapy. It’s estimated that 75 percent of women with advanced ovarian cancer initially respond to chemotherapy treatment, but the majority will relapse within two years.

0 comments posted

Preventive Surgery For Breast and Ovarian Cancers May Become a Thing of the Past

By Admin at 14 Oct 2015

Preventive surgery is a drastic cancer solution, however, which carries a risk of both physical and psychological consequences. In the case of ovarian cancer, it’s possible the surgery may also not entirely prevent the cancer from forming. Alternatives to lower cancer risk in women with BRCA 1 and BRCA2 mutations are greatly needed, and two new studies offer potential solutions.

0 comments posted

    Categories

    Archive

    2018 2017 2016 2015
    99 cents of every dollar received directly funds cancer clinical trials

    58

    Current Gateway-funded clinical trials

    150+

    Clinical trials funded at leading institutions worldwide

    $16.56

    Funds one patient for one day at a Gateway-funded clinical trial

     
     

    Mission Partners